Jump to content

Alatrofloxacin: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Chemcol (talk | contribs)
219 edits
No edit summary
Chemcol (talk | contribs)
219 edits
No edit summary
Line 54: Line 54:
}}
}}


'''Alatrofloxacin''' is a bioactive molecule of 4-pyridone group that inhibits bacterial type IIA topoisomerase (DNA gyrase and topoisomerase IV).<ref name="10.3389/fphar.2019.00835">{{cite journal|first1=Abed|last1=Forouzesh|first2=Sadegh|last2=Samadi Foroushani|first3=Fatemeh|last3=Forouzesh|first4=Eskandar|last4=Zand|title=Reliable target prediction of bioactive molecules based on chemical similarity without employing statistical methods|journal=Frontiers in Pharmacology|date=2019|doi=10.3389/fphar.2019.00835|volume=10|pages=835|pmid=31404334|pmc=6676798}}</ref> Alatrofloxacin (Trovan IV) is a [[fluoroquinolone antibiotic]] developed by [[Pfizer]], delivered as a [[mesylate]] [[salt (chemistry)|salt]].<ref>{{cite web|title=Center for Drug Evaluation and Research {{ndash}} Application Number: 020759/020760 {{ndash}} Chemistry Review(s)|publisher=[[Food and Drug Administration]]|url=http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_chemr.pdf|accessdate=29 August 2014}}</ref>
'''Alatrofloxacin''' is a [[bioactive]] [[molecule]] of 4-pyridone group that inhibits [[bacteria]]l type IIA [[topoisomerase]] ([[DNA gyrase]] and [[topoisomerase IV]]).<ref name="10.3389/fphar.2019.00835">{{cite journal|first1=Abed|last1=Forouzesh|first2=Sadegh|last2=Samadi Foroushani|first3=Fatemeh|last3=Forouzesh|first4=Eskandar|last4=Zand|title=Reliable target prediction of bioactive molecules based on chemical similarity without employing statistical methods|journal=Frontiers in Pharmacology|date=2019|doi=10.3389/fphar.2019.00835|volume=10|pages=835|pmid=31404334|pmc=6676798}}</ref> Alatrofloxacin (Trovan IV) is a [[fluoroquinolone antibiotic]] developed by [[Pfizer]], delivered as a [[mesylate]] [[salt (chemistry)|salt]].<ref>{{cite web|title=Center for Drug Evaluation and Research {{ndash}} Application Number: 020759/020760 {{ndash}} Chemistry Review(s)|publisher=[[Food and Drug Administration]]|url=http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_chemr.pdf|accessdate=29 August 2014}}</ref>


Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in June of 2006.
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in June of 2006.

Revision as of 20:11, 24 August 2019

Alatrofloxacin
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa605016
Routes of
administration		Intravenous
ATC code
  • none
Legal status
Legal status
  • Withdrawn
Pharmacokinetic data
BioavailabilityN/A
Protein binding76% (trovafloxacin)
MetabolismQuickly hydrolyzed to trovafloxacin
Elimination half-life9 to 12 hours (trovafloxacin)
ExcretionFecal and renal (trovafloxacin)
Identifiers
  • 7-[(1R,5S)-6-{[(2S)-1-{[(2S)-2-Aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
CAS Number
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC26H25F3N6O5
Molar mass558.509 g/mol g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@H]1[C@H]2[C@@H]1CN(C2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F)N
  • InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1 ☒N
  • Key:UUZPPAMZDFLUHD-VUJLHGSVSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Alatrofloxacin is a bioactive molecule of 4-pyridone group that inhibits bacterial type IIA topoisomerase (DNA gyrase and topoisomerase IV).[1] Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[2]

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in June of 2006.

See also

References

  1. ^ Forouzesh, Abed; Samadi Foroushani, Sadegh; Forouzesh, Fatemeh; Zand, Eskandar (2019). "Reliable target prediction of bioactive molecules based on chemical similarity without employing statistical methods". Frontiers in Pharmacology. 10: 835. doi:10.3389/fphar.2019.00835. PMC 6676798. PMID 31404334.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  2. ^ "Center for Drug Evaluation and Research – Application Number: 020759/020760 – Chemistry Review(s)" (PDF). Food and Drug Administration. Retrieved 29 August 2014.


Stub icon

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Alatrofloxacin&oldid=912330323"